THE GOAL OF THIS PROPOSED RESEARCH IS TO DEFINE THE MOLECU- LAR STRUCTURES THAT DETERMINE THE ANTIGENETIC REACTIVITY OF THE HUMAN RH SYSTEM.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
4981
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Gene Labs Inc
871 Industrial Road, Building J, San Carlos, CA, 94070
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
KOU M HWANG
PRINCIPAL INVESTIGATOR
(415) 594-1600
Business Contact:
() -
Research Institution:
n/a
Abstract
THE GOAL OF THIS PROPOSED RESEARCH IS TO DEFINE THE MOLECU- LAR STRUCTURES THAT DETERMINE THE ANTIGENETIC REACTIVITY OF THE HUMAN RH SYSTEM. USING PREEXISTING HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST A LARGE G DETERMINANT AND ONE DIRECTED AGAINST A DETERMINANT FOUND ON RH D+ CELLS BUT NOT DU CELLS, GENE LABS WILL REFINE THE CHARACTERIZATION OF THE HUMAN RH SYSTEM. IN ADDITION TO THE ABOVE ANTIBODIES, MORE ANTIBODIES DIRECTED AGAINST DETERMINANTS OF THE RH SYSTEM WILL BE MADE. THIS WILL BE DONE USING A HUMAN MYELOMA FUSION PARTNER TO IMMORTALIZE SENSITIZED LYMPHOCYTES OBTAINED FROM RH IMMUNE DONORS. THE GENES FOR THESE ANTI- BODIES WILL THEN BE MANIPULATED BY A VARIETY OF DNA CLONING TECHNIQUES TO INCREASE THE AFFINITY AND TO SWITCH THE ISOTYPES. AFTER SUCCESSFUL COMPLETION OF THE FIRST PHASE OFTHIS WORK, GENE LABS WILL EXTEND THE WORK TO PROVIDE A COMMERCIAL SUPPLY OF HUMAN MONOCLONAL ANTI-RH REAGENTS FOR BLOOD TYPING AND FOR THERAPY OF HEMOLYTIC DISEASE OF THE NEWBORN AND AUTOIMMUNE HEMOLYTIC ANEMIA.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government